Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia  Marc A. Mueller, Frank Beutner, Daniel.

Slides:



Advertisements
Similar presentations
Lukasova M. et al. J Clin Invest 2011;121:
Advertisements

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Novel Inhibitory Effect of Naloxone on Macrophage.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Mycophenolate Mofetil Decreases Atherosclerotic Lesion.
Macrophage ABCA2 deletion modulates intracellular cholesterol deposition, affects macrophage apoptosis, and decreases early atherosclerosis in LDL receptor.
Maternal protein restriction during pregnancy and lactation in rats imprints long-term reduction in hepatic lipid content selectively in the male offspring 
Transglutaminase activity regulates atherosclerotic plaque composition at locations exposed to oscillatory shear stress  Hanke L. Matlung, Annette E.
Influence of apolipoprotein E, age and aortic site on calcium phosphate induced abdominal aortic aneurysm in mice  Yutang Wang, Smriti M. Krishna, Joseph.
Saskia Z. H. Rittersma, Martijn Meuwissen, Chris M
Alpha-lipoic acid inhibits fractalkine expression and prevents neointimal hyperplasia after balloon injury in rat carotid artery  Kyeong-Min Lee, Keun-Gyu.
Anti-oxidant and anti-atherogenic properties of liposomal glutathione: Studies in vitro, and in the atherosclerotic apolipoprotein E-deficient mice  Rosenblat.
LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia  Ilker Tasci, Gokhan Erdem, Gokhan Ozgur, Serkan Tapan, Teoman Dogru,
Maros Ferencik, Yiannis S. Chatzizisis  Atherosclerosis 
Arterioscler Thromb Vasc Biol
Increased amount of bone marrow-derived smooth muscle-like cells and accelerated atherosclerosis in diabetic apoE-deficient mice  J.O. Fledderus, O. van.
Increased atherosclerotic lesion area in apoE deficient mice overexpressing bovine growth hormone  Irene J. Andersson, Anna Ljungberg, Lennart Svensson,
Erkan Söğüt, Hasan Kadı, Metin Karayakalı, Cuma Mertoğlu 
Low-carbohydrate diets reduce lipid accumulation and arterial inflammation in guinea pigs fed a high-cholesterol diet  Jose O. Leite, Ryan DeOgburn, Joseph.
Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta  Päivi.
Omega-6 polyunsaturated fatty acids prevent atherosclerosis development in LDLr-KO mice, in spite of displaying a pro-inflammatory profile similar to.
Evidence for an exclusive association of matrix metalloproteinase-9 with dysfunctional high-density lipoprotein: A novel finding  S. Sini, D. Deepa, S.
Volume 21, Issue 2, Pages (June 2014)
Volume 20, Issue 1, Pages (July 2014)
Systemic Administration of Multipotent Mesenchymal Stromal Cells Reverts Hyperglycemia and Prevents Nephropathy in Type 1 Diabetic Mice  Fernando E. Ezquer,
Volume 2, Issue 2, Pages (August 1998)
NF-κB suppresses the expression of ATP-binding cassette transporter A1/G1 by regulating SREBP-2 and miR-33a in mice  Guo-Jun Zhao, Shi-Lin Tang, Yun-Cheng.
Wip1-Dependent Regulation of Autophagy, Obesity, and Atherosclerosis
Hypoglycemic and hypolipidemic effect and antioxidant activity of chronic epigallocatechin-gallate in streptozotocin-diabetic rats  Mehrdad Roghani, Tourandokht.
A 43kD protein from the herb, Cajanus indicus L
Mary Chatterjee, Kasturi Sarkar, Parames C. Sil  Pathophysiology 
Volume 8, Issue 4, Pages (October 2008)
Volume 18, Issue 2, Pages (April 2011)
Volume 12, Issue 2, Pages (August 2010)
Preconditioning protects the severely atherosclerotic mouse heart
Aromatase is required for female abdominal aortic aneurysm protection
Liver X Receptor Activators Display Anti-Inflammatory Activity in Irritant and Allergic Contact Dermatitis Models: Liver-X-Receptor-Specific Inhibition.
Volume 15, Issue 3, Pages (March 2012)
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety  Stephan.
Volume 35, Issue 5, Pages (November 2011)
Attenuation of early atherosclerotic lesions by immunotolerance with β2 glycoprotein I and the immunomodulatory effectors interleukin 2 and 10 in a murine.
Volume 21, Issue 2, Pages (June 2014)
Volume 12, Issue 2, Pages (August 2010)
Molecular Therapy - Nucleic Acids
Volume 6, Issue 6, Pages (December 2007)
T-cell co-stimulation by CD28–CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development  M.M. Ewing, J.C. Karper,
Volume 14, Issue 10, Pages (March 2016)
Volume 18, Issue 1, Pages (July 2013)
Volume 11, Issue 2, Pages (October 2004)
Volume 7, Issue 2, Pages (February 2008)
Volume 16, Issue 1, Pages 9-13 (June 2009)
Volume 13, Issue 5, Pages (May 2011)
Volume 2, Issue 3, Pages (September 2000)
Kasturi Sarkar, Parames C. Sil  Pathophysiology 
Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus.
Yunmei Wang, Huiyun Gao, Candace M
Volume 9, Issue 5, Pages (May 2009)
Volume 10, Issue 1, Pages (July 2009)
Leptin: A pivotal mediator of intestinal inflammation in mice
Liver X Receptor Activators Display Anti-Inflammatory Activity in Irritant and Allergic Contact Dermatitis Models: Liver-X-Receptor-Specific Inhibition.
Volume 15, Issue 3, Pages (March 2012)
Erratum to “Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice” [Int J Cardiol 139.
Induction of Angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis  Shinji Tanaka, Jack R. Wands, Shigeki.
Emre Seli, M. D. , Ozlem Guzeloglu-Kayisli, Ph. D. , Umit A
Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley  Kidney International 
Fig. 2. CD treatment facilitates regression of murine atherosclerosis.
Fig. 5 Nec-1 therapy decreases atherosclerotic lesion progression and markers of instability in Apoe−/− mice. Nec-1 therapy decreases atherosclerotic lesion.
Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist  Scott E. Wenderfer, Stanislaw.
Figure 1 Correlation between en face Oil-Red O staining and aortic root lesion size vs. plasma cholesterol and ... Figure 1 Correlation between en face.
Characterization of LDLR−/− control and Western-diet offspring at birth and at 90 days of age. Characterization of LDLR−/− control and Western-diet offspring.
Volume 23, Issue 10, Pages (June 2018)
Volume 1, Issue 5, Pages (May 2005)
Presentation transcript:

Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia  Marc A. Mueller, Frank Beutner, Daniel Teupser, Uta Ceglarek, Joachim Thiery  Atherosclerosis  Volume 198, Issue 1, Pages 39-48 (May 2008) DOI: 10.1016/j.atherosclerosis.2007.09.019 Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 Atherosclerotic lesion area in the aortic root (a) and the brachiocephalic artery (b) of male LDL-receptor−/− mice fed a 0.1% cholesterol diet for 14 weeks and receiving solvent (group A), everolimus 0.05mg (group B) or 1.5mg/kg/bodyweight per day (group C). Atheroma development was quantified morphometrically in five equidistant sections of the aortic root and in three equidistant sections of the brachiocephalic artery by computerized oil red O stained sections. Each datapoint represents the mean of the lesion size from one individual animal. The lines represent means of the individual data points in group A, B and C. Atherosclerosis 2008 198, 39-48DOI: (10.1016/j.atherosclerosis.2007.09.019) Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 Effect of everolimus on the complexity of atherosclerotic lesions of the brachiocephalic artery in LDL-receptor knockout mice fed a 0.1% cholesterol diet over 14 weeks. The animals received either solvent (group A, n=19) or everolimus (0.05mg/kg body weight per day group B, n=15; or 1.5mg/kg/bw per day group C, n=13) over a period of 12 weeks. χ2-test group A vs. group B, p<0.01, group A vs. group C, p<0.001; group B vs. group C, p<0.01. The morphological results are based on sections from the same region of the artery. Atherosclerosis 2008 198, 39-48DOI: (10.1016/j.atherosclerosis.2007.09.019) Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

Fig. 3 Effect of everolimus on the lesion development in LDLR−/− mice. Animals were placed on a 0.1% cholesterol-rich diet and solvent (group A), everolimus 0.05mg (group B) or 1.5mg/kg/bodyweight per day (group C) was administered over a period of 12 weeks. The mice were sacrificed and the aortic root (magnification ×10, Fig. 3a) and the brachiocephalic artery (magnification ×10, Fig. 3b) were fixed, sectioned, stained with oil red O (ORO), Movat's pentachrome (MOVAT) or immunostained with CD68-antibodys (CD68) and used for morphometric analyses. The photographs reflect one representative animal of each investigated group and the morphological findings for the three different staining methods were taken from the same region of the artery in all three groups. Atherosclerosis 2008 198, 39-48DOI: (10.1016/j.atherosclerosis.2007.09.019) Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

Fig. 4 Total cholesterol and cholesterol levels of plasma lipoproteins (LDL-, VLDL, and HDL) isolated from EDTA-plasma at 20 weeks of age in male LDLR−/− C57Bl/6 mice on a 0.1% cholesterol diet, receiving solvent (group A), everolimus 0.05mg (group B) or 1.5mg/kg/bw per day (group C). Atherosclerosis 2008 198, 39-48DOI: (10.1016/j.atherosclerosis.2007.09.019) Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

Fig. 5 Effect of everolimus on circulating cell mediators in plasma. Plasma cytokines, growth factors and chemokines were measured in individual plasma samples of each animal. Everolimus treatment resulted in a significant reduction of plasma interleukin-1a [IL-1a], interleukin-5 [IL-5], granulocyte-monocyte colony–stimulating factor [GM-CSF] and dose dependant for interleukin-12p40 [IL-12p40]. An increase of keratinocyte-derived chemokine [KC] was observed by treatment with everolimus in group B (34.8±28.8; p=n.s.) and in group C (59.0±36.1pg/ml; p<0.001). For all other investigated cytokines, growth factors and chemokines, everolimus treatment did not change the circulating plasma levels of cell mediators. Atherosclerosis 2008 198, 39-48DOI: (10.1016/j.atherosclerosis.2007.09.019) Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions